Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-Cell Transcriptomic Profiling Reveals Immunometabolic Reprogramming and Cell-Cell Communication in the Tumor Microenvironment of Human Hepatocellular Carcinoma.

International journal of molecular sciences·2026
Same author

Canonical Pathways Rewiring in Alzheimer's Disease.

International journal of molecular sciences·2026
Same author

Two Cohorts, One Network: Consensus Master Regulators Orchestrating Papillary Thyroid Carcinoma.

International journal of molecular sciences·2025
Same author

Identifying Key Features Associated with Excessive Fructose Intake: A Machine Learning Analysis of a Mexican Cohort.

Nutrients·2025
Same author

Pro-Inflammatory and Anti-Inflammatory Interleukins in Periodontitis: Molecular Roles, Immune Crosstalk, and Therapeutic Perspectives.

International journal of molecular sciences·2025
Same author

Computational Metagenomics: State of the Art.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 10, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.1K

Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.

Joel Ruiz-Hernández1,2, Guillermo de Anda-Jáuregui1,3, Enrique Hernández-Lemus1

  • 1División de Genómica Computacional, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.

International Journal of Molecular Sciences
|November 27, 2025
PubMed
Summary
This summary is machine-generated.

This study identifies potential drug candidates for repositioning to treat cervical cancer by analyzing gene expression patterns associated with high-risk human papillomavirus (HPV) clades A7 and A9. Findings offer new therapeutic avenues for HPV-driven cervical cancers.

Keywords:
HPV cladesOCTAD frameworkcervical cancerdrug repurposinghuman papillomavirusprecision oncologysystems biologytranscriptomic signatures

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.1K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.1K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.1K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.9K

Area of Science:

  • Oncology
  • Virology
  • Pharmacology

Background:

  • Cervical cancer is a significant global health issue, primarily caused by persistent high-risk human papillomavirus (HPV) infections.
  • Biological variations between HPV clades A7 and A9 may impact cervical cancer development and patient outcomes.

Purpose of the Study:

  • To identify Food and Drug Administration (FDA)-approved drugs for repositioning against cervical cancer.
  • To explore potential pharmacological candidates by analyzing expression-based drug repurposing strategies.

Main Methods:

  • Utilized the OCTAD (Open Cancer Therapeutic Discovery) framework for an expression-based drug repurposing approach.
  • Constructed disease transcriptional signatures for HPV clades A7 and A9.
  • Compared disease signatures with drug perturbation profiles to identify compounds with inverse expression associations.

Main Results:

  • Identified 41 drug candidates for HPV clade A7 and 52 for HPV clade A9.
  • Found stronger transcriptomic reversal correlated with increased drug sensitivity in cell lines.
  • Enriched drug classes included histone deacetylase inhibitors, estrogen pathway modulators, and statins.

Conclusions:

  • Revealed shared and clade-specific vulnerabilities in HPV-driven cervical cancers.
  • Demonstrated the effectiveness of expression-based repurposing for generating therapeutic hypotheses.
  • Provided a resource of drug candidates for preclinical validation in HPV-positive cervical cancer models.